Overcoming immunological tolerance to melanoma: Targeting CTLA-4-Reference-Cited by-同舟云学术

Overcoming immunological tolerance to melanoma: Targeting CTLA-4

Published:2010-03 Issue: Volume:6 Page:S16-S23
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:

Author:

HODI F Stephen

Publisher

Wiley

Subject

Oncology,General Medicine

Reference38 articles.

1. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma;Clemente;Cancer,1996

2. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response;Mihm;Lab Invest,1996

3. Anti-CTLA4 antibody clinical trials in Melanoma;Ribas;Update Cancer Ther,2007

4. Cytotoxic T-lymphocyte-associated antigen-4;Hodi;Clin Cancer Res,2007

5. Checkpoint blockade in cancer immunotherapy;Korman;Adv Immunol,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?;Current Treatment Options in Oncology;2024-05-16

2. Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients;Journal of Translational Medicine;2023-05-11

3. Sicca symptoms and sialoadenitis as immune-related adverse events of nivolumab treatment in renal malignancy;MOJ Clinical & Medical Case Reports;2023-03-27

4. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412;Clinical Cancer Research;2022-10-03

5. Immune Checkpoints in Cancers: From Signaling to the Clinic;Cancers;2021-09-12